Erectile Dysfunction Drugs Market Research Report - Global Forecast till 2027

Erectile Dysfunction Drugs Market Research Report: Information by Drugs (Viagra (sildenafil citrate), Cialis (Tadalafil), Staxyn/Levitra (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), and Others), End User (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2027

ID: MRFR/Pharma/0805-HCR | February 2021 | Region: Global | 80 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data.

Erectile Dysfunction Drugs Market Scenario


Global erectile dysfunction drugs market is expected to register a CAGR of 3.5% during the forecast period of 2019 to 2025 with a market value of USD 2930 million in 2025.


Erectile dysfunction (ED) is defined as persistent difficulty achieving and maintaining an erection sufficient to have sex.


The global erectile dysfunction drugs market is driven by factors such as increasing number of men suffering from this disorder, rising geriatric population and patent expiry of number of blockbuster drugs.


Additionally, increasing manufactures of generic drugs coupled with rising adoption of a sedentary lifestyle along with the associated stress is anticipated to fuel the market growth.


For instance, according to The Massachusetts Male Aging Study (MMAS), worldwide incidence of erectile dysfunction will increase from 152 million men in 1995 to 322 million men by the year 2025.


On the other hand, poor patient adherence to erectile dysfunction drugs is projected to hamper the growth of the market during the assessment period.


Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.


For instance, in December 2017, Teva Pharmaceutical Industries Ltd. announces exclusive launch of a generic version viagra tablets in the US.


Erectile Dysfunction Drugs Market Segmentation


The global erectile dysfunction drugs market has been segmented based on and region.


The market, based on drug, has been bifurcated into viagra (sildenafil citrate), cialis (tadalafil), staxyn/levitra (vardenafil), stendra/spedra (avanafil), zydena (udenafil), vitaros (alprostadil cream), and others. The market, on the basis of end user, has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Based on drug, viagra segment is expected to hold a major share in the market as it is the first Food and Drug Administration (FDA) approved oral treatment for erectile dysfunction. In 1998, Pfizer introduced viagra which is dominating the erectile dysfunction market. Cialis segment is expected to be the fastest growing segment as cialis provides an erection over a longer period than viagra, cialis lasts up to 18 hours, while viagra only lasts for about 4 to 6 hours.


On the basis of end user retail pharmacy segment is expected to be the largest segment as it is available easily in the retail stores. The hospital pharmacy segment is expected to be the fastest growing segment as increasing pool of patient due to increasing awareness and patient education.


The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The erectile dysfunction drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European erectile dysfunction drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The erectile dysfunction drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The erectile dysfunction drugs market in the Middle East & Africa has been divided into the Middle East and Africa.


Key Players


The key players in the global erectile dysfunction drugs market are Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.


Regional Market Summary


Global Erectile Dysfunction Drugs Market Share by Region, 2018 (%)


Source: World Health Organization (WHO)


The market in the Americas is expected to dominate the global erectile dysfunction drugs market due to the rising prevalence of erectile dysfunction and increasing awareness & patient education in the region. High cases of erectile dysfunction in the US and Canada is expected to drive the market growth. For example, as per the survey, overall prevalence of erectile dysfunction in men aged more than 20 years was 18.4% suggesting that erectile dysfunction affects 18 million men in the US. Furthermore, increasing expenses in research by healthcare bodies engaged in research of novel drugs is expected to fuel the growth of the market in this region. The market in Europe showed a considerable amount of growth. This can be attributed to the increasing adoption of a sedentary lifestyle along with the associated stress in the European region. The market in Asia-Pacific is projected to have a fastest growth rate during the forecast period owing to the increasing geriatric population and rising availability of generic drugs. For example, according to The United Nations Population Fund, by 2050, 1 in 4 people in Asia and the Pacific will be over 60 years old. The population of older people (aged over 60) in the region will triple between 2010 and 2050 and will reach close to 1.3 billion people. The incidences of erectile dysfunction increase with the growing age hence Asia-Pacific market will grow fast in the forecasted period. The market in the Middle East & Africa is projected to account for the least share of the global market due to low awareness and patient education in the region.


Global Erectile Dysfunction Drugs Market, by Drug



  • Viagra (sildenafil citrate)

  • Cialis (Tadalafil)

  • Staxyn/Levitra (vardenafil)

  • Stendra/Spedra (avanafil)

  • Zydena (udenafil)

  • Vitaros (Alprostadil Cream)

  • Others


Global Erectile Dysfunction Drugs Market, by Equipment



  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy


Global Erectile Dysfunction Drugs Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Research and development (R&D) companies

  • Medical device companies

  • Government research institutes

  • Academic institutes and universities

  • Venture capitalists



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 2930 Million
  • 2027: Significant Value
  •   CAGR   3.5% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Drugs and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.
      Key Market Opportunities   poor patient adherence to erectile dysfunction drugs
      Key Market Drivers

  • increasing number of men suffering from this disorder
  • rising geriatric population
  • patent expiry of number of blockbuster drugs


  • Frequently Asked Questions (FAQ) :


    Erectile dysfunction drugs market is estimated to reach USD 2930 MN by 2025.

    Erectile dysfunction drugs market is estimated to grow at 3.5% CAGR during the forecast period (2019-2025).

    North America holds the largest share in the global erectile dysfunction drugs market followed by Europe and Asia Pacific, respectively.

    Apricus Biosciences Inc., Pfizer, Inc., Bayer AG, Dong-A Pharmaceutical Co. Ltd., Cristalia Produtos Quimicos Farmaceuticos Ltd., Eli Lilly and Company, S.K. Chemicals Co. Ltd., Meda Pharmaceuticals, Inc., Vivus, Inc., and Teva Pharmaceutical Industries Ltd., are some of the major players operating in the global erectile dysfunction drugs market.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Overview

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    Chapter 6. Global Erectile Dysfunction Drugs Market, by Drug

    6.1 Overview

    6.2 Viagra (sildenafil citrate)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Cialis (Tadalafil)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Staxyn/Levitra (vardenafil)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5 Stendra/Spedra (avanafil)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.6 Zydena (udenafil)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.7 Vitaros (Alprostadil Cream)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.8 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 7. Global Erectile Dysfunction Drugs Market, by End User

    7 .1 Overview

    7 .2 Hospital Pharmacy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7 .3 Retail Pharmacy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7 .4 Online Pharmacy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Erectile Dysfunction Drugs Market, by Region

    8 .1 Overview

    8 .2 Americas

    8 .2.1 North America

    8 .2.1.1 US

    8 .2.1.2 Canada

    8 .2.2 Latin America

    8 .3 Europe

    8 .3.1 Western Europe

    8 .3.1.1 Germany

    8 .3.1.2 France

    8 .3.1.3 Italy

    8 .3.1.4 Spain

    8 .3.1.5 UK

    8 .3.1.6 Rest of Western Europe

    8 .3.2 Eastern Europe

    8 .4 Asia-Pacific

    8 .4.1 Japan

    8 .4.2 China

    8 .4.3 India

    8 .4.4 Australia

    8 .4.5 South Korea

    8 .4.6 Rest of Asia-Pacific

    8 .5 Middle East & Africa

    8 .5.1 Middle East

    8 .5.2 Africa

    Chapter 9. Company Landscape

    9.1 Overview

    9.2 Competitive Analysis

    Chapter 10. Company Profile

    10.1 Pfizer, Inc.

    10.1.1 Company Overview

    10.1.2 Product Type Overview

    10.1.3 Financial Overview Overview

    10.1.4 Key Developments

    10.1.5 SWOT Analysis

    10.2 Apricus Biosciences Inc.

    10.2.1 Company Overview

    10.2.2 Product Type Overview

    10.2.3 Financial Overview

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.3 Bayer AG

    10.3.1 Company Overview

    10.3.2 Product Type Overview

    10.3.3 Financial Overview

    10.3.4 Key Developments

    10.3.5 SWOT Analysis

    10.4 Cristalia Produtos Quimicos Farmaceuticos Ltd.

    10.4.1 Company Overview

    10.4.2 Product Type Overview

    10.4.3 Financial Overview

    10.4.4 Key Developments

    10.4.5 SWOT Analysis

    10.5 Dong-A Pharmaceutical Co. Ltd.

    10.5.1 Company Overview

    10.5.2 Product Type Overview

    10.5.3 Financial overview

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.6 Eli Lilly and Company

    10.6.1 Company Overview

    10.6.2 Product Type Overview

    10.6.3 Financial Overview

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.7 Meda Pharmaceuticals, Inc.

    10.7 .1 Overview

    10.7 .2 Product Type Overview

    10.7 .3 Financial Overview

    10.7 .4 Key Developments

    10.7 .5 SWOT Analysis

    10.8 S.K. Chemicals Co. Ltd.

    10.8.1 Overview

    10.8.2 Product Type Overview

    10.8.3 Financial Overview

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.9 Vivus, Inc.

    10.9.1 Overview

    10.9.2 Product Type Overview

    10.9.3 Financial Overview

    10.9.4 Key Developments

    10.9.5 SWOT Analysis

    10.10 Teva Pharmaceutical Industries Ltd.

    10.10.1 Overview

    10.10.2 Product Type Overview

    10.10.3 Financial Overview

    10.10.4 Key Developments

    10.10.5 SWOT Analysis

    10.11 Others

    Chapter 11 Appendix

    11.1 References

    11.2 Related Reports


    LIST OF TABLES

    Table 1 Global Erectile Dysfunction Drugs Market Synopsis, 2020-2027

    Table 2 Global Erectile Dysfunction Drugs Market Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 4 Global Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 5 Global Erectile Dysfunction Drugs Market, by Region, 2020-2027 (USD Million)

    Table 6 North America: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 7 North America: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 8 US: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 9 US: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 10 Canada: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 11 Canada: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 12 Latin America: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 13 Latin America: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 14 Europe: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 15 Europe: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 16 Western Europe: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 17 Western Europe: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 18 Eastern Europe: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 19 Eastern Europe: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 20 Asia-Pacific: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 21 Asia-Pacific: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)

    Table 22 Middle East & Africa: Erectile Dysfunction Drugs Market, by Drug, 2020-2027 (USD Million)

    Table 23 Middle East & Africa: Erectile Dysfunction Drugs Market, by End User, 2020-2027 (USD Million)  

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Market Structure of the Global Erectile Dysfunction Drugs Market

    Figure 3 Market Dynamics of the Global Erectile Dysfunction Drugs Market

    Figure 4 Global Erectile Dysfunction Drugs Market Share, by Type, 2020 (%)

    Figure 5 Global Erectile Dysfunction Drugs Market Share, by End User, 2020 (%)

    Figure 6 Global Erectile Dysfunction Drugs Market Share, by Region, 2020 (%)

    Figure 7 North America: Erectile Dysfunction Drugs Market Share, by Country, 2020 (%)

    Figure 8 Europe: Erectile Dysfunction Drugs Market Share, by Region, 2020 (%)

    Figure 9 Western Europe: Erectile Dysfunction Drugs Market Share, by Country, 2020 (%)

    Figure 10 Asia-Pacific: Erectile Dysfunction Drugs Market Share, by Country, 2020 (%)

    Figure 11 Middle East & Africa: Erectile Dysfunction Drugs Market Share, by Country, 2020 (%)

    Figure 12 Global Erectile Dysfunction Drugs Market: Company Share Analysis, 2020 (%)

    Figure 13 Pfizer, Inc.: Key Financial Overview

    Figure 14 Pfizer, Inc.: Segmental Revenue

    Figure 15 Pfizer, Inc.: Geographic Revenue

    Figure 16 Apricus Biosciences Inc.: Key Financial Overview

    Figure 17 Apricus Biosciences Inc.: Segmental Revenue

    Figure 18 Apricus Biosciences Inc.: Geographic Revenue

    Figure 19 Bayer AG: Key Financial Overview

    Figure 20 Bayer AG: Segmental Revenue

    Figure 21 Bayer AG: Geographic Revenue

    Figure 22 Cristalia Produtos Quimicos Farmaceuticos Ltd.: Key Financial Overview

    Figure 23 Cristalia Produtos Quimicos Farmaceuticos Ltd.: Segmental Revenue

    Figure 24 Cristalia Produtos Quimicos Farmaceuticos Ltd.: Geographic Revenue

    Figure 25 Dong-A Pharmaceutical Co. Ltd.: Key Financial Overview

    Figure 26 Dong-A Pharmaceutical Co. Ltd.: Segmental Revenue

    Figure 27 Dong-A Pharmaceutical Co. Ltd.: Geographic Revenue

    Figure 28 Eli Lilly and Company: Key Financial Overview

    Figure 29 Eli Lilly and Company: Segmental Revenue

    Figure 30 Eli Lilly and Company: Geographic Revenue

    Figure 31 Meda Pharmaceuticals, Inc.: Key Financial Overview

    Figure 32 Meda Pharmaceuticals, Inc.: Segmental Revenue

    Figure 33 Meda Pharmaceuticals, Inc.: Geographic Revenue

    Figure 34 S.K. Chemicals Co. Ltd.: Key Financial Overview

    Figure 35 S.K. Chemicals Co. Ltd.: Segmental Revenue

    Figure 36 S.K. Chemicals Co. Ltd.: Geographic Revenue

    Figure 37 Vivus, Inc.: Key Financial Overview

    Figure 38 Vivus, Inc.: Segmental Revenue

    Figure 39 Vivus, Inc.: Geographic Revenue

    Figure 40 Teva Pharmaceutical Industries Ltd.: Key Financial Overview

    Figure 41 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

    Figure 42 Teva Pharmaceutical Industries Ltd.: Geographic Revenue